Venous thromboembolism (VTE) is the third most common cause of death worldwide. The
incidence of VTE varies according to different countries, ranging from 1–2 per 1000 person …

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

The incidence of venous thromboembolism (VTE) in cancer patients may have changed in
the past decade, possibly due to novel cancer therapies, improved survival, and high …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Background Patients with active cancer have an increased risk of venous thromboembolism,
which results in substantial morbidity, mortality, and health care expenditures. The Khorana …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

Background Venous thromboembolism is a common complication of cancer, but the risk of
develo** venous thromboembolism varies greatly among individuals and depends on …

Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among
these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …